HIV protease inhibitors in combination with boceprevir: Are drug-drug interactions the same for all patients?

AIDS

Volumn 26, Issue 14, 2012, Pages 1845-1846

  Schwarze Zander, Carolynne ^a   Rockstroh, Jürgen K ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELAPREVIR;

DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MIXED INFECTION; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD; VIRUS RESISTANCE;

DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV PROTEASE INHIBITORS; HUMANS; LIVER CIRRHOSIS; PROLINE; VIRAL LOAD;

EID: 84866338216     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328357065c     Document Type: Letter

References (11)

1. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
2. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
3. Dieterich D, Soriano V, Sherman K, Girard PM, Rockstroh J, Adiwijaya B, et al., on behalf of the Study 110 Team. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR Interim Analysis. 19th Conference on Retrovirus and Opportunistic Infections, March 5-8 2012; abstract 46.
4. Mallolas J, Pol S, Rivero A, Fainboim H, Cooper C, Slim J, et al. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients: end of treatment (Week 48) interim results. 47th Annual Meeting of the European Association for the Study of the Liver 2012; abstract 50.
5. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11:179-185.
6. FDA Drug Safety Communication. Important drug interactions between Victrelis (boceprevir) and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitor drugs. FDA Safety Announcement 2012.
7. Hulskotte E, Feng H-P, Xuan F, van Zutven M, O'Mara E, Youngberg S, et al. Pharmakokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, Lopinavir and Darunavir. 19th Conference on Retrovirus and Opportunistic Infections, March 5-8 2012; abstract 77 1LB.
8. Reddy SSK. Results of Pharmacokinetic Study in Healthy Volunteers Given Victrelis (boceprevir) and Ritonavir-Boosted HIV Protease Inhibitors May Indicate Clinically Significant Drug Interactions for Patients Coinfected with Chronic Hepatitis C and HIV. Dear Healthcare Professional Letter 2012; February 6, 2012.
9. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical Pharmacology of BOC: Metabolism, Excretion, and Drug-Drug Interactions. 18th Conference on Retrovirus and Opportunistic Infections, February 27-March 2 2011; abstract 118.
10. Micheli V, Regazzi M, Dickinson L, Meraviglia P, Villani P, Khoo SH, et al. Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. Ther Drug Monit 2008; 30:306-313.
11. Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, et al. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. J Antimicrob Chemo-ther 2007; 60:831-836. (Pubitemid 47434263)